NCT00457795View on ClinicalTrials.gov

24-hour IOP-lowering Effect of Brimonidine 0.1%

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

brimonidine 0.1% (Alphagan® P)

Brimonidine 0.1%, 1 drop three-times daily for 4 weeks

Trial Locations (1)

Unknown

San Diego

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00457795 - 24-hour IOP-lowering Effect of Brimonidine 0.1% | Biotech Hunter | Biotech Hunter